Sionna Therapeutics (NASDAQ:SION) Shares Down 4.2% – What’s Next?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price was down 4.2% during trading on Monday . The company traded as low as $13.11 and last traded at $13.11. Approximately 40,547 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 232,004 shares. The stock had previously closed at $13.69.

Wall Street Analyst Weigh In

SION has been the topic of several recent analyst reports. Guggenheim assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price on the stock. TD Cowen began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating on the stock. Finally, Stifel Nicolaus started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price objective for the company.

Sionna Therapeutics Price Performance

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.